Gault Cheryl sold $416K of RAPP
Gault Cheryl (Chief Operating Officer) sold 10,000 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $41.58 ($40.09–$43.15, $0.42M total) across 4 trades on 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is a new, primary datapoint for insider activity, but the 10b5-1 designation generally limits fundamental inference.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a durable repricing without additional catalysts.
What to watch
The article provides sale size and price range but not the broader context (e.g., total insider activity over the last 6–12 months), which can matter for interpreting whether this is unusual.
Background
The article is an SEC Form 4 insider transaction disclosure for Rapport Therapeutics, Inc. (RAPP).
Ticker impact
SEC Form 4 shows COO Cheryl Gault sold 10,000 shares of Rapport Therapeutics on 2026-06-30 under a 10b5-1 plan, ~$415.8K total value.
Likely limited immediate price impact; any effect would be sentiment-driven and should fade unless accompanied by other news.
The filing is a primary-source insider transaction with disclosed size and pricing range, but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.
Market effects
No broader sector read-through; this is company-specific insider dealing.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations; traders may overreact if they treat it as discretionary selling.
Key entities
- issuerRapport Therapeutics, Inc.
Subject of the Form 4 insider transaction; COO Cheryl Gault sold shares under a 10b5-1 plan.
- insiderCheryl Gault
Chief Operating Officer who executed open-market sales totaling ~$415.8K.
